The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 05, 2019
Filed:
Jul. 12, 2017
Applicant:
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Inventors:
Kenneth J. Barr, Boston, MA (US);
Corey E. Bienstock, Natick, MA (US);
John K. Maclean, Brookline, MA (US);
Hongjun Zhang, Newton, MA (US);
Richard T. Beresis, Shanghai, CN;
Dongshan Zhang, Shanghai, CN;
Neville J. Anthony, Northborough, MA (US);
Blair T. Lapointe, Brookline, MA (US);
Yuan Tian, Boston, MA (US);
Assignee:
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 209/26 (2006.01); C07D 231/56 (2006.01); C07D 471/04 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 409/04 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01); C07D 401/06 (2006.01); C07D 403/06 (2006.01); C07D 405/06 (2006.01); C07D 413/06 (2006.01); A61K 31/404 (2006.01); A61K 31/416 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/5377 (2006.01); C07D 405/12 (2006.01);
U.S. Cl.
CPC ...
C07D 209/26 (2013.01); A61K 31/404 (2013.01); A61K 31/416 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/5377 (2013.01); C07D 231/56 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 409/04 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); Y02A 50/409 (2018.01);
Abstract
The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.